Maxigen Biotech (TPE:1783) ROCE % : 7.46% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Maxigen Biotech's annualized ROCE % for the quarter that ended in Mar. 2024 was 7.46%.

Maxigen Biotech ROCE % Historical Data

The historical data trend for Maxigen Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech ROCE % Chart

Maxigen Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

8.93

8.88

9.67

13.56

14.53

Maxigen Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															11.34	18.32	16.40	6.95	7.46

Maxigen Biotech ROCE % Calculation

Maxigen Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	193.142	/	( ( (1447.723 - 151.5)	+	(1492.986 - 131.373) )	/ 2 )
	=	193.142	/	( (1296.223	+	1361.613)	/ 2 )
	=	193.142	/	1328.918
	=	14.53 %

Maxigen Biotech's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	101.348	/	( ( (1492.986 - 131.373)	+	(1489.75 - 135.991) )	/ 2 )
	=	101.348	/	( ( 1361.613	+	1353.759 )	/ 2 )
	=	101.348	/	1357.686
	=	7.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Maxigen Biotech (TPE:1783) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Maxigen Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Maxigen Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Maxigen Biotech (TPE:1783) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88, Keji 1st Rd, Guishan District, Taoyuan City, TWN, 333

Website

https://www.mbi.com.tw

Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is primarily engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products.

Maxigen Biotech (TPE:1783) Headlines

No Headlines